Deswal Monica, Lekhwani Seema, Vaswani Narain D, Bala Kiran, Kaushik Jaya S
Department of Pediatrics, Pt. B D Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.
Department of Biochemistry, Pt. B D Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India.
Ann Indian Acad Neurol. 2022 Sep-Oct;25(5):916-920. doi: 10.4103/aian.aian_481_22. Epub 2022 Oct 31.
To compare the efficacy of oral dexamethasone and prednisolone in the treatment of newly diagnosed children aged 3-36 months of West syndrome.
An open-labeled, randomized controlled clinical trial with parallel group assignment was conducted among children aged 3-36 months with newly diagnosed West syndrome. They were randomized to receive either oral dexamethasone (0.6 mg/kg/day QID) (n = 20) or oral prednisolone (4 mg/kg/day BD) (n = 20). Proportion of children who achieved spasm freedom at 2 weeks was the primary outcome. Secondary outcome measures were proportion of children who achieved electroclinical resolution, greater than 50% reduction in spasms frequency, time to cessation of spasms, and adverse effects at 2 weeks.
The efficacy of oral dexamethasone was comparable to oral prednisolone in terms of proportion of children who achieved spasms cessation (13 [65%] vs. 8 [40%]; = 0.21), electroclinical remission (13 [65%] vs. 8 [40%] = 0.21), greater than 50% reduction of spasms (3 [15%] vs. 7 [35%] = 0.65), and time to cessation of spasms (5.31 [2.81] vs. 4.37 [1.41] = 0.39). Adverse effect profile was also comparable with irritability (18 [90%] vs. 12 [60%] = 0.06] being most common.
There was no difference in electroclinical remission at 2 weeks between oral dexamethasone and prednisolone in children with infantile spasms in this small pilot trial. Further evaluation is suggested with an adequately powered study and long-term follow-up.
比较口服地塞米松和泼尼松龙治疗新诊断的3至36个月大儿童韦斯特综合征的疗效。
对新诊断为韦斯特综合征的3至36个月大儿童进行了一项开放标签、随机对照的平行组分配临床试验。他们被随机分为接受口服地塞米松(0.6毫克/千克/天,每日4次)(n = 20)或口服泼尼松龙(4毫克/千克/天,每日2次)(n = 20)。在2周时实现痉挛自由的儿童比例是主要结局。次要结局指标包括实现电临床缓解的儿童比例、痉挛频率降低超过50%的儿童比例、痉挛停止时间以及2周时的不良反应。
在实现痉挛停止的儿童比例(13例[65%]对8例[40%];P = 0.21)、电临床缓解(13例[65%]对8例[40%],P = 0.21)、痉挛频率降低超过50%(3例[15%]对7例[35%],P = 0.65)以及痉挛停止时间(5.31[2.81]对4.37[1.41],P = 0.39)方面,口服地塞米松的疗效与口服泼尼松龙相当。不良反应情况也相似,易怒最为常见(18例[90%]对12例[60%],P = 0.06)。
在这项小型试验中,口服地塞米松和泼尼松龙治疗婴儿痉挛症儿童2周时的电临床缓解情况无差异。建议进行有足够样本量的研究和长期随访以作进一步评估。